ORPHA:199323
Endophthalmitis
Publications
30,113
Trials
33
Interventional, condition-specific
Researchers
1,047
Distinct authors in sample
Gene link
—
Readiness
5/6
Stages with a signal
Clinical definition (Orphanet)
A rare ophthalmic disorder characterized by inflammation involving the vitreous and/or aqueous humors, usually due to bacterial or fungal infection. It may arise endogenously from hematogenous spread of the infectious agent, or exogenously after direct inoculation, and can take an acute or chronic course. Clinical signs and symptoms include vitritis, hypopyon, reduced or blurred vision, red eye, pain, and lid swelling. The condition may be complicated by panophthalmitis, corneal infiltration and perforation, affection of orbital structures, and phthisis bulbi.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0016047
- MeSH:D009877
- UMLS:C0014236
- NCIT:C34586
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
5/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
30,113 matched papers (16,091 in last 10 years) Source
- Phenotype characterisedPresent
32 HPO annotations (e.g. Reduced visual acuity; Corneal perforation; Deep anterior chamber) Source
- Animal modelPresent
3 genotype models (Rattus norvegicus) Source
- Orphan designationPresent
3 FDA designations (3 FDA orphan-indication approvals) — e.g. povidone iodine Source
- Interventional trialPresent
33 matched on ClinicalTrials.gov (1 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
32
Associated phenotypes · MONDO:0016047
- Reduced visual acuity
- Corneal perforation
- Deep anterior chamber
- Blurred vision
- Herpetiform corneal ulceration
Showing 5 of 32 — open Monarch for the full list.
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
3
Designations · 3 with FDA orphan-indication approval
- FDA povidone iodineEndophthalmitis · 2018-11-30 · Not FDA Approved for Orphan Indication
- FDA povidone iodineEndophthalmitis · 2017-11-27 · Not FDA Approved for Orphan Indication
- FDA vancomycinEndophthalmitis · 2012-12-27 · Not FDA Approved for Orphan Indication
Sources: FDA OOPD · EMA orphan designations
Open Targets candidates
4
Drugs / clinical candidates · MONDO_0016047
- LEVOFLOXACIN·phase 1 2
- LIDOCAINE·unknown
- MOXIFLOXACIN·phase 1 2
- POVIDONE-IODINE·unknown
CTD chemicals (MyDisease.info)
13 associated chemicals. Therapeutic evidence is listed first when present — not a treatment recommendation.
- Amikacin · therapeutic
- Azathioprine · therapeutic
- Cefuroxime · therapeutic
- Cyclophosphamide · therapeutic
- Gentamicins · therapeutic
- liposomal amphotericin B · therapeutic
- Prednisolone · therapeutic
- Tobramycin · therapeutic
- Vancomycin · therapeutic
- Alendronate · marker/mechanism
- Cocaine · marker/mechanism
- Methamphetamine · marker/mechanism
Literature
Is anyone studying this?
30,113
30,113 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
30,113 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
16,091 in the last 10 years · low confidence
Phrase hits: 30,113 · MeSH hits: 745
Who's working on it?
1,047
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Flynn HW Jr10 papers · 2026
Department of Ophthalmology, Bascom Palmer Eye Institute, Miami, FL, USA.
Papers in Europe PMC - 02Zhang Y7 papers · 2026
Ningbo Key Laboratory of Biomedical Imaging Probe Materials and Technology, Laboratory of Advanced Theranostic Materials and Technology, Ningbo Institute of Materials Technology and Engineering, Chinese Academy of Sciences, Ningbo 315201, China.
Papers in Europe PMC - 03Bari A6 papers · 2026Papers in Europe PMC
- 04Miller D5 papers · 2026
Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, 900 Northwest 17th Street, Miami, FL, 33136, USA.
Papers in Europe PMC - 05Rohowetz LJ5 papers · 2026
Department of Ophthalmology, Bascom Palmer Eye Institute, Miami, FL, USA.
Papers in Europe PMC - 06Zhang C5 papers · 2026
Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, United States.
Papers in Europe PMC - 07Wu H4 papers · 2026
Department of Ophthalmology, the Second Hospital of Jilin University, Changchun, Jilin, China.
Papers in Europe PMC - 08Yannuzzi NA4 papers · 2026
Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller, School of Medicine, 900 NW 17th Street, Miami, FL, 33136, USA.
Papers in Europe PMC - 09Zhang X4 papers · 2026
Henan Eye Hospital, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, China.
Papers in Europe PMC - 10Zhou Y4 papers · 2026
Department of Ophthalmology, University of Florida, Gainesville, FL, USA.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
33
interventional trials for this specific condition
33 interventional trials matched this specific condition name; 1 currently recruiting in our sample.
Data as of 11 September 2026
33 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 96.2th percentile).
low confidence · 96.2th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
33 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT03244072·NOT YET RECRUITING·Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery
Not reviewed·Conditions: Endophthalmitis·Matched via name + MeSH
Observational and natural-history studies
20 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT06673784·NOT YET RECRUITING·Evaluation and Risk Factors of Post-traumatic Endophthalmitis
Not reviewed·Conditions: Endophthalmitis·Matched via name + MeSH
- NCT05372861·RECRUITING·Nanopore Sequencing in Ophthalmology
Not reviewed·Conditions: Endophthalmitis·Matched via name + MeSH
- NCT07175311·RECRUITING·Vascular Changes Associated With Endophthalmitis.
Not reviewed·Conditions: Endophthalmitis·Matched via name + MeSH
- NCT05432336·RECRUITING·Complex Ocular Infection, Optimization of Microbiological Diagnosis
Not reviewed·Conditions: Endophthalmitis · Keratitis·Matched via name + MeSH
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 30 · after dedupe 30 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 30 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (30)
- ctis·2026-525594-39-00·Authorised·Multicenter, randomized, double-blind, parallel-group clinical study comparing RD03/2016 (levoFloxacin and ketorolac trometAmol) eye drops vs Leviosa® (levofloxacin and dexamethaSone 21-phosphaTe) eye drops for 7 days for the prevention and treatment of inflammation and prevention of infection associated with cataract surgery in adults.
(FAST 7)
skipped — LLM skipped (--skip-llm)
- ctis·2024-513983-24-00·Authorised, ongoing·EMMA - Medico Economic Evaluation of Fluocinolone Acetonide Implant Versus Dexametheasone Implant in Resistant Diabetic Macular Oedema
skipped — LLM skipped (--skip-llm)
- ctis·2024-511885-35-00·Cancelled·TELeMAC - Comparative multicenter randomized study of aflibercept versus placebo in macular telangiectasia type 1
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN13314346·No longer recruiting·Intracorneal prosthesis for corneal blindness
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN56596656·Not yet recruiting·Combination antifungal therapy for candida bloodstream infections
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17116576·Recruiting·A nationwide clinical trial for patients with the eye condition vitreous haemorrhage due to proliferative diabetic retinopathy investigating whether early eye surgery and laser treatment is a safe and better option for improving visual outcomes than the current standard of care
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12693443·Recruiting·Treatment of severe Diabetic macular oedema with Anti-vascular endothelial growth factor (anti-VEGF) monotherapy versus treatment with anti-VEGF followed by subthreshold Micropulse lasEr when the thickness of the central retina goes below 400 microns: a pragmatic randomised equivalence trial
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN59733193·No longer recruiting·ReNEW: a clinical trial investigating the efficacy and safety of elamipretide in subjects who have dry age-related macular degeneration (Dry AMD)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN38641780·No longer recruiting·A study to compare JNJ-81201887 to a sham procedure for the treatment of geographic atrophy secondary to age-related macular degeneration
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15871371·No longer recruiting·A study to assess the safety, biological activity, tolerability and processing by the body of RO7200394 in participants with macular edema secondary to central retinal vein occlusion
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17422545·No longer recruiting·‘iCam’ polymerase chain reaction (PCR) testing for rapid diagnosis of eye infections
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN42621450·No longer recruiting·Study to assess safety and efficacy of ADVM-022 in patients having already received anti-VEGF treatment for neovascular (wet) age-related macular degeneration (nAMD) [LUNA]
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN69073386·No longer recruiting·A study evaluating the effectiveness and safety of faricimab (RO6867461) in participants with polypoidal choroidal vasculopathy
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12839469·No longer recruiting·A study to characterize the impact of dietary modification on inavolisib associated hyperglycaemia and to assess the CYP3A4 induction potential of inavolisib using midazolam as a probe substrate in participants with incurable metastatic solid tumours previously treated with multiple (≥2) lines of therapy
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN21989763·No longer recruiting·Biomaterial made from fish scales for short-term closure of defects affecting the entire thickness of the cornea
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14152148·No longer recruiting·Study of the safety, tolerability, processing by the body, and ability to provoke immune system response of ocular injections of RO7446603 alone and in combination with aflibercept or faricimab in participants with diabetic macular edema
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11595117·No longer recruiting·A study evaluating single-agent inavolisib and inavolisib plus atezolizumab in PIK3CA-mutated cancers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN45319897·No longer recruiting·A study to evaluate the safety, tolerability, processing by the body, and antitumor activity of inavolisib and paclitaxel
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN87195453·No longer recruiting·A comparison of two treatment regimes for the treatment of fungal eye infections in East Africa
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14424997·No longer recruiting·New techniques for reducing intraocular pressure spike after intravitreal injection of bevacizumab
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14332621·No longer recruiting·Chlorhexidine 0.2% vs natamycin 5% for the treatment of fungal corneal infections
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN13623634·No longer recruiting·The LEAVO study
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN40512708·No longer recruiting·Corneal Glue Study: effect of corneal adhesive on preventing fluid ingress after cataract surgery
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN84613089·No longer recruiting·Intracameral voriconazole injection in the treatment of fungal endophthalmitis developed from keratitis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN41154297·No longer recruiting·Efficacy and Safety Assessment of Azyter® (T1225) in Peri-Operative Antibio-Prophylaxis (ocular surface decontamination) for Cataract Surgery
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Endophthalmitis — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Endophthalmitis"
MeSH descriptor terms unioned into the query: Endophthalmitis
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Endophthalmitis"
Interventional trials matched via: both (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 33 interventional · 20 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is short or not clearly distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (30113) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T09:13:18.588Z
